Skip to main content
. 2018 Jun 8;16(2):730–738. doi: 10.3892/etm.2018.6274

Figure 1.

Figure 1.

Expression of CYR-61 in NSCLC and normal lung cell line and the characteristics of anti-CYR-61. (A) Reverse transcription-quantitative polymerase chain reaction and western blot analyses were used to analyze the expression of CYR-61 in H358 NSCLC cells and MRC-5 normal lung cells. Data are presented as the mean ± SD of triplicate samples. (B) Fluorescence-activated cell sorting was used to screen anti-CYR-61affinity. 1st, 2nd and 3rd represent the population of CYR-61 positive cells 1, 2 and 3 h after anti-CYR-61 treatment, respectively. (C) ELISA was used to analyze the affinity of anti-CYR-61 for its target protein, CYR-61. Data are presented as the mean ± SD of triplicate samples. (D) Western blotting was used to analyze the purified anti-CYR-61. **P<0.01 vs. MRC-5 cells. CYR-61, cysteine-rich angiogenic inducer-61; SD, standard deviation; TERTR-FAM96A, telomerase reverse transcriptase-family with sequence similarity 96 member A; NSCLC, non-small cell lung cancer.